logo-loader
HealthPharma & Biotech
Horizon Discovery Group PLC

Horizon Discovery Group bids farewell to Abcam founder who exits board following failed bid approach

Jonathan Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"

boardroom table
Will Horizon look to fill the vacant non-executive director position or leave the seat vacant

It was all very cordial, but there was an air of inevitability about the departure of Dr Jonathan Milner from the board of gene editing specialist Horizon Discovery Group PLC (LON:HZD).

For those unaware of the background, Abcam PLC (LON:ABC), the company founded by Milner, recently launched an unwelcome £270mln bid for Horizon that ultimately failed.

Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"

Enthusiastic about the future 

"I continue to be encouraged and enthusiastic about the growth prospects of Horizon's business, and intend to remain a shareholder for the foreseeable future," he went on.

Horizon chairman Dr Ian Gilham for his part said he was sorry to see Milner depart, but understood the decision to prioritise "other commitments"

"We are extremely grateful for his valuable insights as a member of Horizon's board over many years and wish him well in his future, not least as a considerable founding shareholder of the Horizon business."

 

Quick facts: Horizon Discovery Group PLC

Price: £1.58

Market: AIM
Market Cap: £237.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights licenses electronic data capture software to UK...

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing...

2 days, 11 hours ago

2 min read